| COMPANY |
West Pharmaceutical Services, Inc. |
| COURT |
United States District Court for the Eastern District of Pennsylvania |
| CASE NUMBER |
2:25-cv-02285 |
| JUDGE |
The Hon. Juan Ramon Sánchez |
| CLASS PERIOD |
February 16, 2023 through February 12, 2025 |
| SECURITY TYPE |
Common Stock |
LEAD PLAINTIFF DEADLINE IS JULY 7, 2025.
If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.
Case Background:
A class action lawsuit was filed on behalf of those who purchased or otherwise acquired West Pharmaceutical Services, Inc. (“West”) (NYSE: WST) common stock between February 16, 2023, and February 12, 2025, inclusive (the “Class Period”).
West is a medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West categorizes its Proprietary Products segment into three categories: (1) High-Value Product (“HVP”) components; (2) HVP delivery devices; and (3) standard products. HVP components include vial seals, vial stoppers, and syringe plungers under West brands such as FluroTec, NovaPure, and Westar. HVP delivery devices are advanced drug systems that include the company’s SmartDose devices. West’s Contract Manufacturing (“CM”) segment consists of custom drug delivery systems and device assemblies produced according to customers’ proprietary designs and specifications. As part of West’s CM business, West develops continuous glucose monitoring (“CGM”) devices for its customers.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (2) West’s SmartDose device was highly dilutive to the company’s profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including the company’s exit from CGM contracts with long-standing customers; and (4) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
What is a Lead Plaintiff?
A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.